Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration
视网膜发色团的不可水解类似物;
基本信息
- 批准号:9899990
- 负责人:
- 金额:$ 35.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:11 cis RetinalAge related macular degenerationAldehydesAll-Trans-RetinolAlternative TherapiesAminesAnimal ModelAnimalsApoproteinsAttenuatedBindingBinding SitesBiochemicalBiochemical ReactionBiological AssayBlindnessBrainBypassCaenorhabditis elegansCarbonCarrier ProteinsCattleCellsChemicalsChloridesCognitiveComplexCultured CellsCyclic AMPDark AdaptationDegenerative DisorderDevelopmentDietDigestionDiseaseDrug KineticsDrug or chemical Tissue DistributionElectroretinographyEnzymesEventExhibitsExposure toEyeFunctional disorderGTP-Binding ProteinsGeneticHealthHigh Pressure Liquid ChromatographyHistologicHumanImaging TechniquesImpairmentIn SituIn VitroIncubatedIsomerismKnowledgeLasersLeber&aposs amaurosisLightLightingMass Spectrum AnalysisMediatingMembraneMethodsModelingMonitorMouse ProteinMusNatural regenerationNatureNitrogenOphthalmoscopyOpsinOptical Coherence TomographyOral AdministrationPhotonsPhotoreceptorsPhysiologyPigmentsPropertyProteinsRecoveryRecyclingReportingRetinaRetinal DegenerationRetinal DiseasesRetinal PigmentsRetinitis PigmentosaRetinoidsRetinol Binding ProteinsRhodopsinRodRoleScanningSchiff BasesSeriesSerumSignal TransductionSorsby&aposs fundus dystrophyStargardt&aposs diseaseTestingTherapeuticToxic effectVisionVisualVitamin AVitamin A Deficiencyabsorptionanalogbasechemical synthesischromophorecombatdesensitizationearly onsetmouse modelnon-invasive imagingnon-invasive monitornovelnovel therapeuticspreservationpreventprotective effectprotein activationpublic health relevanceregenerativeretinal rodsrisk minimizationrod outer segment discside effectstemtwo photon microscopyuptakevisual cycle
项目摘要
DESCRIPTION (provided by applicant): An insufficient supply of visual chromophore due to dysfunction of key proteins involved in its regeneration has devastating effects on rod-mediated vision, and comprises a leading cause of irreversible blindness in humans. Early signs of such blinding diseases are delayed rod cell-mediated dark adaptation and difficulty with night vision. The decline in recovery of visual sensitivity is likely caused by inadequate Rho regeneration with accumulation of chromophore-free opsin that constitutively activates the signaling cascade and accelerates retinal degeneration. Although such free opsin activity can be reduced by exogenous retinal chromophore, this fails to prevent the buildup of toxic retinoid photo-products when their clearance is defective. Thus, an alternative therapeutic approach is urgently needed for combating vision loss under such conditions. Here we propose to investigate the effects of new visual pigments, retinyl-opsins regenerated with novel chromophore analogs, retinyl chlorides on retina physiology in context of potential therapeutic strategy to protect retinal healh in retinal degenerative diseases associated with compromised Rho regeneration. First, we will study the biochemical and functional properties of different retinyl chloride isomers in vitro (Aim
1), and then test the effects of selected retinyl chlorides in both Abca4-/-Rdh8-/- mice, a model of early onset human Stargardt disease and in Lrat-/- mice, a model of Leber congenital amaurosis (LCA) (Aim 2). Finally, we will assess the capability of the RBP4 carrier to increase the ocular delivery of these compounds, and thereby alleviate progressive retinal degeneration in these mouse models (Aim 3).
描述(由适用提供):由于其再生所涉及的关键蛋白功能障碍引起的视觉发色团供应不足,对杆介导的视力产生了毁灭性的影响,并且是人类不可逆失明的主要原因。这种盲疾病的早期迹象是延迟的杆细胞介导的黑暗适应性,并且在夜视范围内很难。视觉敏感性恢复的下降可能是由于Rho再生不足而引起的,而无色蛋白的积累则可以组成式地激活信号传导级联并加速视网膜变性。尽管外源残留的发色团可以降低这种自由的Opsin活性,但在清除有缺陷时,这无法防止有毒的类维生素性照片产生产生。这是在这种情况下迫切需要一种替代治疗方法来打击视力丧失。在这里,我们建议研究新的视觉色素,新型视网膜粘蛋白,与新型的发色团类似物,视乙酰氯化物再生,在潜在的治疗策略中保护与损害Rho Rho再生有关的视网膜退行性疾病中的视网膜疗法的潜在治疗策略。首先,我们将研究体外不同视乙酰氯异构体的生化和功能特性(AIM
1),然后测试选定的视乙酰氯化物在ABCA4 - / - RDH8 - / - 小鼠中的作用,早期发作的人类Stargardt疾病和LRAT - / - 小鼠的模型,即Leber先天性阿莫斯菌(LCA)的模型(AIM 2)。最后,我们将评估RBP4载体增加这些化合物的眼部输送的能力,从而减轻这些小鼠模型的渐进性视网膜变性(AIM 3)。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Beata Jastrzebska其他文献
Beata Jastrzebska的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Beata Jastrzebska', 18)}}的其他基金
Novel neuroprotective activities of flavonoids against retinal degenerative diseases
黄酮类化合物对视网膜退行性疾病的新型神经保护活性
- 批准号:
10704506 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Novel neuroprotective activities of flavonoids against retinal degenerative diseases
黄酮类化合物对视网膜退行性疾病的新型神经保护活性
- 批准号:
10428740 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration
视网膜发色团的不可水解类似物;
- 批准号:
9026350 - 财政年份:2016
- 资助金额:
$ 35.66万 - 项目类别:
相似国自然基金
基于“肝—眼轴”的枸杞子及其复方防治青少年近视与年龄相关性黄斑变性的功效物质与生物学机制研究
- 批准号:U21A20408
- 批准年份:2021
- 资助金额:260.00 万元
- 项目类别:
基于“肝-眼轴”的枸杞子及其复方防治青少年近视与年龄相关性黄斑变性的功效物质与生物学机制研究
- 批准号:
- 批准年份:2021
- 资助金额:260 万元
- 项目类别:
PGF突变介导的周细胞与内皮细胞crosstalk在湿性年龄相关性黄斑变性中的作用及机制研究
- 批准号:82000898
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
组织病理结构与临床检查对照观察在指导渗出性年龄相关性黄斑变性诊治中的意义研究
- 批准号:81400409
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
基于多模态医学影像技术的湿性年龄相关性黄斑变性诊断与分析
- 批准号:81371629
- 批准年份:2013
- 资助金额:75.0 万元
- 项目类别:面上项目
相似海外基金
Polypharmacological approach to treatment of Stargardt disease
治疗 Stargardt 病的多药理学方法
- 批准号:
10561110 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Modulation of retinoid reactivity and pathological signaling in retinal therapeutics
视网膜治疗中类维生素A反应性和病理信号的调节
- 批准号:
9891782 - 财政年份:2020
- 资助金额:
$ 35.66万 - 项目类别:
Modulation of retinoid reactivity and pathological signaling in retinal therapeutics
视网膜治疗中类维生素A反应性和病理信号的调节
- 批准号:
10454758 - 财政年份:2020
- 资助金额:
$ 35.66万 - 项目类别:
Modulation of retinoid reactivity and pathological signaling in retinal therapeutics
视网膜治疗中类维生素A反应性和病理信号的调节
- 批准号:
10618853 - 财政年份:2020
- 资助金额:
$ 35.66万 - 项目类别:
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration
视网膜发色团的不可水解类似物;
- 批准号:
9026350 - 财政年份:2016
- 资助金额:
$ 35.66万 - 项目类别: